3T Biosciences

3T Biosciences

  • Founded: 2017
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Solid tumors
  • Drug types: ONC, IMM, VAC, INF
  • Lead product: Undisclosed
  • Product link: https://3tbiosciences.com/science/
  • Funding: $40M A Aug 2022; $12M seed Oct 2017
  • Investors: Westlake Village BioPartners, Lightspeed Venture Partners



job board

Short description:

TCR Therapies

Drug notes:

Undisclosed programs RD autoimmune diseases, viral infections

Long description:

3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy. 3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com